Effect of alcohol exposure on the efficacy and safety of tenofovir alafenamide fumarate, a major medicine against human immunodeficiency virus.
Effect of alcohol exposure on the efficacy and safety of tenofovir alafenamide fumarate, a major medicine against human immunodeficiency virus.
复制标题
DOI:
10.1016/j.bcp.2022.115224
复制
发表时间:
2022-10
影响因子:
5.8
通讯作者:
Yan, Bingfang
中科院分区:
文献类型:
--
作者:
Liu, William;Yu, Sarah;Yan, Bingfang
关键词:
Human immunodeficiency virus (HIV) continues to be a major health concern. AIDS-related deaths (acquired immunodeficiency syndrome) have decreased recently, but chronic liver disease is now a major cause of mortality among HIV patients. Widespread alcohol use is recognized to be a major contributing factor. Tenofovir alafenamide fumarate (TAF), one of the most used HIV drugs, requires hydrolysis followed by phosphorylation to produce tenofovir diphosphate, the ultimate anti-HIV metabolite. Carboxylesterase-1 (CES1), established to hydrolyze TAF, is known to catalyze transesterification in the presence of ethanol. The aim of the study was to test the hypothesis that metabolism-based interactions between TAF and ethanol negatively impact both efficacy and safety of TAF. To test this hypothesis, the metabolism of TAF was determined in human primary hepatocytes and with a large number of human liver samples (S9 fractions) in the presence or absence of ethanol. The metabolism was monitored by LC-MS/MS (liquid chromatography with tandem mass spectrometry) and the level of CES1 or CES2 was determined by Western blotting. Consistent with the hypothesis, TAF underwent transesterification in the presence of ethanol accompanied by decreased hydrolysis. The formation of tenofovir diphosphate (the therapeutically active metabolite) was significantly decreased. In addition, TAF but not its hydrolytic metabolite, was found to increase intracellular lipid retention, and the increase was enhanced by ethanol. These findings conclude that alcohol consumption, beyond commonly accepted poor adherence to HIV medications, directly impacts the efficacy and safety of TAF.
登录
查看更多内容
影响因子:
--
作者:
Chowta MN;Kamath P;Ramapuram JT;Shenoy KA;Hadigal S
通讯作者:
Hadigal S
DOI:
10.1177/23259582211044920
发表时间:
2021-01
影响因子:
--
作者:
Brown JL;Anastasakis I;Revzina N;Capasso A;Boeva E;Rassokhin V;Crusey A;Sales JM;Hitch A;Renfro T;DiClemente RJ
通讯作者:
DiClemente RJ
影响因子:
3.9
作者:
Jaiswal J;Dunlap K;Griffin M;Cox A;Singer SN;Hascher K;LoSchiavo C;Walters SM;Mumba M
通讯作者:
Mumba M
影响因子:
2.9
作者:
Bavinton BR;Mahendra IGAA;Kaldor J;Law M;Grulich AE;Januraga PP
通讯作者:
Januraga PP
影响因子:
3.3
作者:
Duko, Bereket;Toma, Alemayehu;Abraham, Yacob
通讯作者:
Abraham, Yacob